Literature DB >> 9740787

Dominant host range selection of vaccinia recombinants by rescue of an essential gene.

G W Holzer1, W Gritschenberger, J A Mayrhofer, V Wieser, F Dorner, F G Falkner.   

Abstract

We report the rescue of a defective vaccinia virus, forming the basis for a stringent selection protocol to generate replicating recombinant virus without the need for marker cassettes and selection agents. Plaques of recombinant virus could be isolated solely by their ability to grow in wild-type cells normally supporting the growth of vaccinia virus. All growth-competent clones analyzed contained the gene of interest in the intended genomic locus and displayed foreign gene expression to the same levels as was seen with classical recombinants obtained by insertion into the vaccinia virus thymidine kinase locus. The system is based on a defective vaccinia virus, expressing exclusively early genes, termed eVAC-1, and an insertion plasmid vector providing the essential function, the uracil DNA glycosylase gene. In addition, the defective virus is free of selection and color marker genes, thus also representing a basic vector for the generation of defective recombinants. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9740787     DOI: 10.1006/viro.1998.9307

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  13 in total

1.  Recombinant vaccinia viruses. Design, generation, and isolation.

Authors:  C C Broder; P L Earl
Journal:  Mol Biotechnol       Date:  1999-12-15       Impact factor: 2.695

2.  Highly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expression.

Authors:  G W Holzer; G Remp; G Antoine; M Pfleiderer; O M Enzersberger; W Emsenhuber; T Hämmerle; F Gruber; C Urban; F G Falkner; F Dorner
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

3.  Use of a negative selectable marker for rapid selection of recombinant vaccinia virus.

Authors:  Stacy D White; Kip Conwell; Jeffrey O Langland; Bertram L Jacobs
Journal:  Biotechniques       Date:  2011-05       Impact factor: 1.993

4.  A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.

Authors:  Annett Hessel; Michael Schwendinger; Daniela Fritz; Sogue Coulibaly; Georg W Holzer; Nicolas Sabarth; Otfried Kistner; Walter Wodal; Astrid Kerschbaum; Helga Savidis-Dacho; Brian A Crowe; Thomas R Kreil; P Noel Barrett; Falko G Falkner
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

5.  Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.

Authors:  Josef Mayrhofer; Sogue Coulibaly; Annett Hessel; Georg W Holzer; Michael Schwendinger; Peter Brühl; Marijan Gerencer; Brian A Crowe; Shen Shuo; Wanjing Hong; Yee Joo Tan; Barbara Dietrich; Nicolas Sabarth; Helga Savidis-Dacho; Otfried Kistner; P Noel Barrett; Falko G Falkner
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

6.  Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.

Authors:  Simone Hornemann; Olof Harlin; Caroline Staib; Sigrid Kisling; Volker Erfle; Bernd Kaspers; Georg Häcker; Gerd Sutter
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

7.  Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.

Authors:  B T Ober; P Brühl; M Schmidt; V Wieser; W Gritschenberger; S Coulibaly; H Savidis-Dacho; M Gerencer; F G Falkner
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

8.  An efficient method for generating poxvirus recombinants in the absence of selection.

Authors:  Amanda D Rice; Stacey A Gray; Yu Li; Inger Damon; Richard W Moyer
Journal:  Viruses       Date:  2011-03       Impact factor: 5.048

9.  Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity.

Authors:  Annett Hessel; Michael Schwendinger; Georg W Holzer; Klaus K Orlinger; Sogue Coulibaly; Helga Savidis-Dacho; Marie-Luise Zips; Brian A Crowe; Thomas R Kreil; Hartmut J Ehrlich; P Noel Barrett; Falko G Falkner
Journal:  PLoS One       Date:  2011-01-24       Impact factor: 3.240

10.  Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever.

Authors:  Birgit Schäfer; Georg W Holzer; Alexandra Joachimsthaler; Sogue Coulibaly; Michael Schwendinger; Brian A Crowe; Thomas R Kreil; P Noel Barrett; Falko G Falkner
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.